Below is a detailed overview of the most compelling findings Saxenda (Liraglutide): Proven for Moderate Weight Loss Saxenda, one of the earliest GLP-1 agonists approved for obesity treatment, was evaluated in the SCALE Obesity and Prediabetes trial , which followed 3,713 participants over 56 weeks
10.1016/j.mcna.2021.06.008 185
Additionally, the sustained improvements in glycemic control and comorbidity resolution observed in our cohort, despite partial WR, highlight the complex physiological effects of SG beyond simple restriction
That P value of 0.2 means this increase was not statistically significant at the lowest dose
Frequently asked questions Is it normal to still feel hungry on semaglutide
But there is some evidence that GLP-1 agonists like semaglutide may decrease cancer risk beyond just their ability to help people lose weight